Business
Neurocrine Biosciences to Present ONGENTYS® (opicapone) and INGREZZA® (valbenazine) Data at the American Neurological Association 2021 Virtual Annual Meeting
SAN DIEGO, Oct. 16, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its movement
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"SAN DIEGO, Oct. 16, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its movement disorder treatments for Parkinson's disease and tardive dyskinesia (TD) at the American Neurological Association (ANA) 2021 Virtual Annual Meeting being held October 17–19, 2021.\n\n \n \n \n \n \n \n\n \nNeurocrine Biosciences will present new post-hoc analysis of pooled data from the ONGENTYS® (opicapone) BIPARK-1 and BIPARK-2 Phase 3 studies evaluating nighttime \"off\" episodes in people with Parkinson's disease and motor fluctuations. The analysis found that a high percentage of study participants prior to initiation of therapy experienced \"off\" time before sleep, had an awake period in an \"off\" state at night after falling asleep, or awoke in the morning in an \"off\" state. Key insights from this analysis provide a better understanding of the effect of wearing \"off\" time on sleep and the importance of addressing nighttime \"off\" episodes in people living with Parkinson's disease. \n\n \"We continue to conduct new analyses and share new insights for INGREZZA and ONGENTYS that not only describe the impact of treatment on disease, but also enable us to better understand the real-life experiences of people living with tardive dyskinesia or Parkinson's disease and the impact of these disorders on their everyday life,\" said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. \"The information presented here underscores our ongoing commitment to help improve the lives of people living with neurological disorders.\"\n\n \n Presentations include:\n \n\n \n ONGENTYS – Parkinson's Disease (in collaboration with BIAL)\n \n\n - Off-time and sleep in Patients with Parkinson's Disease and Motor Fluctuations (Poster # 172)- Effects of Once-Daily Opicapone 50 mg on the Pharmacokinetics of Levodopa Administered as Carbidopa/Levodopa Extended-Release Capsules: An Open-Label Phase 1 Study (Poster # 157)- Evaluating Patients' Preferences for Parkinson's Disease Treatments (Poster # 165)- OPTI-ON: A Longitudinal Real-World Study of Opicapone in Patients with Parkinson's Disease and Motor Fluctuations (Poster # 158)- Treatment Patterns in a Real-World Sample of Patients with Parkinson's Disease and Motor Fluctuations (Poster # 168)\n\n \n INGREZZA – Tardive Dyskin...